Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

White House Slams Generic Exclusivity Provisions In User Fee Bill

Executive Summary

Trump administration says generic exclusivity provisions – which have been softened from the original bill – are unpredictable and could decrease competition; and while the White House is displeased with exclusivity, and wants higher user fees, it is not explicitly threatening a veto.

Advertisement

Related Content

FDARA Takes Effect With Under-The-Radar Presidential Signature
Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill
Opioids: Senate Wants Mandatory Prescriber Training; Can FDA Make It Work?
US FDA 'Medical Innovation Development Plan' Outlined By Gottlieb
Breakthrough-Style Program For ANDAs Added To House User Fee Bill
Trump's Budget Outline Threatens User Fee Agreements

Topics

Advertisement
UsernamePublicRestriction

Register

PS121102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel